Functions of galectin-3 and its role in fibrotic diseases

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 336-343

  Li, Liu Cheng ^a   Li, Jun ^a   Gao, Jian ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; COLLAGEN; GALECTIN 3; LIGAND;

ANGIOGENESIS; APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; FIBROBLAST; FIBROGENESIS; FIBROSIS; HEART MUSCLE FIBROSIS; HUMAN; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SYSTEMIC SCLEROSIS; VASCULAR FIBROSIS; ANIMAL; METABOLISM;

ANIMALS; FIBROSIS; GALECTIN 3; HUMANS;

EID: 84908120931     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218370     Document Type: Review

References (90)

1. Akahani S, Nangia-Makker P, Inohara H, Kim HR, and Raz A (1997) Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57:5272-5276.
2. Aplin AE, Howe A, Alahari SK, and Juliano RL (1998) Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 50:197-263.
3. Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, and Lupón J (2014) Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 63:158-166.
4. Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15:255-273.
5. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, and Rossignol P, et al. (2013) Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33:67-75.
6. Cheung KJ, Libbrecht L, Tilleman K, Deforce D, Colle I, and Van Vlierberghe H (2010) Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol 22:1066-1073.
7. Chiang CK, Hsu SP, Wu CT, Huang JW, Cheng HT, Chang YW, Hung KY, Wu KD, and Liu SH (2011) Endoplasmic reticulum stress implicated in the development of renal fibrosis. Mol Med 17:1295-1305.
8. Conway B and Hughes J (2012) Cellular orchestrators of renal fibrosis. QJM 105:611-615.
9. Cullinane AR, Yeager C, Dorward H, Carmona-Rivera C, Wu HP, Moss J, O'Brien KJ, Nathan SD, Meyer KC, and Rosas IO, et al. (2014) Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosis. Am J Respir Cell Mol Biol 50:605-613.
10. Czaja AJ (2014) Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 20:2515-2532.
11. Dalton P, Christian HC, Redman CW, Sargent IL, and Boyd CA (2007) Membrane trafficking of CD98 and its ligand galectin 3 in BeWo cells-implication for placental cell fusion. FEBS J 274:2715-2727.
12. Danella Polli C, Alves Toledo K, Franco LH, Sammartino Mariano V, de Oliveira LL, Soares Bernardes E, Roque-Barreira MC, and Pereira-da-Silva G (2013) Monocyte migration driven by galectin-3 occurs through distinct mechanisms involving selective interactions with the extracellular matrix. ISRN Inflamm 2013:259256.
13. Dang Z, MacKinnon A, Marson LP, and Sethi T (2012) Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 93:477-484.
14. de Oliveira SA, de Freitas Souza BS, Sá Barreto EP, Kaneto CM, Neto HA, Azevedo CM, Guimarães ET, de Freitas LA, Ribeiro-Dos-Santos R, and Soares MB (2012) Reduction of galectin-3 expression and liver fibrosis after cell therapy in a mouse model of cirrhosis. Cytotherapy 14:339-349.
15. Dong S and Hughes RC (1997) Macrophage surface glycoproteins binding to galectin-3 (Mac-2-antigen). Glycoconj J 14:267-274.
16. Friedman SL, Sheppard D, Duffield JS, and Violette S (2013) Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 5:167sr1.
17. Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, McGinn CM, DePeralta DK, Chen X, and Kuroda T, et al. (2014) Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 59:1577-1590.
18. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Kagawa S, and Raz A (2003) CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 63:8302-8311.
19. Fukumori T, Takenaka Y, Oka N, Yoshii T, Hogan V, Inohara H, Kanayama HO, Kim HR, and Raz A (2004) Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 64:3376-3379.
20. Gao X, Balan V, Tai G, and Raz A (2014) Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. Oncotarget 5:2077-2084.
21. Gumbiner BM (1996) Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 84:345-357.
22. Guo XH, Liu LX, Zhang HY, Zhang QQ, Li Y, Tian XX, and Qiu ZH (2014) Insulin-like growth factor binding protein-related protein 1 contributes to hepatic fibrogenesis. J Dig Dis 15:202-210.
23. Haak AJ, Tsou PS, Amin MA, Ruth JH, Campbell P, Fox DA, Khanna D, Larsen SD, and Neubig RR (2014) Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther 349:480-486.
24. Hao C, Xie Y, Peng M, Ma L, Zhou Y, Zhang Y, Kang W, Wang J, Bai X, and Wang P, et al. (2014) Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo. Clin Exp Med 14:141-150.
25. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, and Sethi T (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103:5060-5065.
26. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, and Sethi T (2008) Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172:288-298.
27. He X, Wang L, Szklarz G, Bi Y, and Ma Q (2012) Resveratrol inhibits paraquatinduced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway. J Pharmacol Exp Ther 342:81-90.
28. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, and Levy D (2012) Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60:1249-1256.
29. Hsu DK, Chernyavsky AI, Chen HY, Yu L, Grando SA, and Liu FT (2009) Endogenous galectin-3 is localized in membrane lipid rafts and regulates migration of dendritic cells. J Invest Dermatol 129:573-583.
30. Hughes RC (1994) Mac-2: a versatile galactose-binding protein of mammalian tissues. Glycobiology 4:5-12.
31. Hynes RO (2009) The extracellular matrix: not just pretty fibrils. Science 326:1216-1219.
32. Inohara H and Raz A (1994) Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11:527-532.
33. Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, Snead A, Lu D, and Aroonsakool N (2012) cAMP and Epac in the regulation of tissue fibrosis. Br J Pharmacol 166:447-456.
34. Jiang JX, Chen X, Hsu DK, Baghy K, Serizawa N, Scott F, Takada Y, Takada Y, Fukada H, and Chen J, et al. (2012) Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol 302:G439-G446.
35. Kapucuoglu N, Basak PY, Bircan S, Sert S, and Akkaya VB (2009) Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol Res Pract 205:97-103.
36. Kasper M and Hughes RC (1996) Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J Pathol 179:309-316.
37. Kikuchi N, Ishii Y, Morishima Y, Yageta Y, Haraguchi N, Itoh K, Yamamoto M, and Hizawa N (2010) Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance. Respir Res 11:31.
38. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, and Chapman HA (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 103:13180-13185.
39. Koca SS, Akbas F, Ozgen M, Yolbas S, Ilhan N, Gundogdu B, and Isik A (2014) Serum galectin-3 level in systemic sclerosis. Clin Rheumatol 33:215-220.
40. Kurotsu S, Tanaka K, Niino T, Asano T, Sugizaki T, Azuma A, Suzuki H, and Mizushima T (2014) Ameliorative effect of mepenzolate bromide against pulmonary fibrosis. J Pharmacol Exp Ther 350:79-88.
41. Lan TH, Huang XQ, and Tan HM (2013) Vascular fibrosis in atherosclerosis. Cardiovasc Pathol 22:401-407.
42. Lee YK, Lin TH, Chang CF, and Lo YL (2013) Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma. PLoS ONE 8:e82478.
43. Liu FT and Hsu DK (2007) The role of galectin-3 in promotion of the inflammatory response. Drug News Perspect 20:455-460.
44. Liu L, Sakai T, Sano N, and Fukui K (2004) Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J 380:31-41.
45. Liu Y (2011) Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7:684-696.
46. Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, André S, Gabius HJ, and Carretero OA (2009) N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growthregulatory lectin. Am J Physiol Heart Circ Physiol 296:H404-H412.
47. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, and van Veldhuisen DJ (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99:323-328.
48. Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, and Lacolley P (2012) Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 14:74-81.
49. Ma B, Kang Q, Qin L, Cui L, and Pei C (2014) TGF-b2 induces transdifferentiation and fibrosis in human lens epithelial cells via regulating gremlin and CTGF. Biochem Biophys Res Commun 447:689-695.
50. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, and Sethi T (2008) Regulation of alternative macrophage activation by galectin-3. J Immunol 180:2650-2658.
51. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, and Gauldie J, et al. (2012) Regulation of transforming growth factor-b1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185:537-546.
52. Maeda N, Kawada N, Seki S, Arakawa T, Ikeda K, Iwao H, Okuyama H, Hirabayashi J, Kasai K, and Yoshizato K (2003) Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem 278:18938-18944.
53. Mallat A and Lotersztajn S (2013) Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol 305:C789-C799.
54. Margadant C, van den Bout I, van Boxtel AL, Thijssen VL, and Sonnenberg A (2012) Epigenetic regulation of galectin-3 expression by b1 integrins promotes cell adhesion and migration. J Biol Chem 287:44684-44693.
55. Martinelli M, Pacilli AM, Rivetti S, Lauriola M, Fasano L, Carbonara P, Mattei G, Valentini I, Scapoli L, and Solmi R (2011) A role for epidermal growth factor receptor in idiopathic pulmonary fibrosis onset. Mol Biol Rep 38:4613-4617.
56. Moncada de la Rosa C, Radziwon-Balicka A, El-Sikhry H, Seubert J, Ruvolo PP, Radomski MW, and Jurasz P (2013) Pharmacologic protein kinase Ca inhibition uncouples human platelet-stimulated angiogenesis from collagen-induced aggregation. J Pharmacol Exp Ther 345:15-24.
57. Mourad-Zeidan AA, Melnikova VO, Wang H, Raz A, and Bar-Eli M (2008) Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 173:1839-1852.
58. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, and Raz A (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899-909.
59. Nathan C and Ding A (2010) Nonresolving inflammation. Cell 140:871-882.
60. Nieminen J, St-Pierre C, and Sato S (2005) Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J Leukoc Biol 78:1127-1135.
61. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, Kawashima S, Tanabe M, Goto T, and Matsuzawa Y, et al. (2007) Role of galectin-3 in human pulmonary fibrosis. Allergol Int 56:57-65.
62. Ochieng J, Furtak V, and Lukyanov P (2004) Extracellular functions of galectin-3. Glycoconj J 19:527-535.
63. Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, and Eddy AA (2011) Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300:F245-F253.
64. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL, and Dennis JW (2004) Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306:120-124.
65. Pera T, Zuidhof AB, Smit M, Menzen MH, Klein T, Flik G, Zaagsma J, Meurs H, and Maarsingh H (2014) Arginase inhibition prevents inflammation and remodeling in a guinea pig model of chronic obstructive pulmonary disease. J Pharmacol Exp Ther 349:229-238.
66. Pilette C, Colinet B, Kiss R, André S, Kaltner H, Gabius HJ, Delos M, Vaerman JP, Decramer M, and Sibille Y (2007) Increased galectin-3 expression and intraepithelial neutrophils in small airways in severe COPD. Eur Respir J 29:914-922.
67. Pricci F, Leto G, Amadio L, Iacobini C, Romeo G, Cordone S, Gradini R, Barsotti P, Liu FT, and Di Mario U, et al. (2000) Role of galectin-3 as a receptor for advanced glycosylation end products. Kidney Int Suppl 77:S31-S39.
68. Rao SP, Wang Z, Zuberi RI, Sikora L, Bahaie NS, Zuraw BL, Liu FT, and Sriramarao P (2007) Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J Immunol 179:7800-7807.
69. Reynolds HY (2005) Lung inflammation and fibrosis: an alveolar macrophage-centered perspective from the 1970s to 1980s. Am J Respir Crit Care Med 171:98-102.
70. Roubille F, Busseuil D, Merlet N, Kritikou EA, Rhéaume E, and Tardif JC (2014) Investigational drugs targeting cardiac fibrosis. Expert Rev Cardiovasc Ther 12:111-125.
71. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, Hirashima M, and Liu FT (2000) Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 165:2156-2164.
72. Sato S and Hughes RC (1992) Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 267:6983-6990.
73. Sato S and Hughes RC (1994) Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J Biol Chem 269:4424-4430.
74. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, and Maessen J, et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121-3128.
75. Shibata T, Noguchi T, Takeno S, Takahashi Y, Fumoto S, and Kawahara K (2005) Impact of nuclear galectin-3 expression on histological differentiation and vascular invasion in patients with esophageal squamous cell carcinoma. Oncol Rep 13:235-239.
76. Speca S, Giusti I, Rieder F, and Latella G (2012) Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 18:3635-3661.
77. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT, and Baum LG (2006) Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176:778-789.
78. Sureshbabu A, Tonner E, Allan GJ, and Flint DJ (2011) Relative roles of TGF-b and IGFBP-5 in idiopathic pulmonary fibrosis. Pulm Med 2011:517687.
79. Tampe D and Zeisberg M (2014) Potential approaches to reverse or repair renal fibrosis. Nat Rev Nephrol 10:226-237.
80. Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Takahashi T, Ichimura Y, Toyama T, and Tamaki Z, et al. (2012) Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol 39:539-544.
81. Téllez-Sanz R, García-Fuentes L, and Vargas-Berenguel A (2013) Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives. Curr Med Chem 20:2979-2990.
82. Todd NW, Luzina IG, and Atamas SP (2012) Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 5:11.
83. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, and Friedman SL (2013) Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS ONE 8:e75361.
84. Wollin L, Maillet I, Quesniaux V, Holweg A, and Ryffel B (2014) Antifibrotic and antiinflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349:209-220.
85. Xue J, Gao X, Fu C, Cong Z, Jiang H, Wang W, Chen T, Wei Q, and Qin C (2013) Regulation of galectin-3-induced apoptosis of Jurkat cells by both O-glycans and N-glycans on CD45. FEBS Lett 587:3986-3994.
86. Yabuta C, Yano F, Fujii A, Shearer TR, and Azuma M (2014) Galectin-3 enhances epithelial cell adhesion and wound healing in rat cornea. Ophthalmic Res 51:96-103.
87. Yang RY, Hsu DK, and Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737-6742.
88. Yang RY, Rabinovich GA, and Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17-e39.
89. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, and Koerts JA, et al. (2013) Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6:107-117.
90. Zuberi RI, Hsu DK, Kalayci O, Chen HY, Sheldon HK, Yu L, Apgar JR, Kawakami T, Lilly CM, and Liu FT (2004) Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol 165:2045-2053.